|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Bipolar Disorder | |||||
| 2 | More general conditions related to this trial | ||||
| Affective Disorders, Psychotic | |||||
| Mental Disorders | |||||
| Mood Disorders | |||||
| 3 | Interventions listed in this trial | ||||
| Tamoxifen Citrate | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Tamoxifen | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Hormonal | |||||
| Bone Density Conservation Agents | |||||
| Estrogen Antagonists | |||||
| Estrogen Receptor Modulators | |||||
| Hormone Antagonists | |||||
| Hormones, Hormone Substitutes, and Hormone Antagonists | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Selective Estrogen Receptor Modulators | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Stanley Medical Research Institute | |||||